A new research perspective was published in Oncotarget’s Volume 15 on February 5, 2024, entitled, “Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma.”
Gene Therapy for Hemophilia B Significantly Outperforms Factor IX Prophylaxis
Gene therapy for hemophilia B allowed almost three-fourths of patients to discontinue prophylactic factor IX therapy with no increase in bleeding, results of the pivotal
September 26, 2024